Skip to main content
TECON BIOLOGY Co.LTD logo

TECON BIOLOGY Co.LTD — Investor Relations & Filings

Ticker · 002100 ISIN · CNE000001PZ9 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,493 across all filing types
Latest filing 2024-10-30 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 002100

About TECON BIOLOGY Co.LTD

https://www.tcsw.com.cn

TECON BIOLOGY Co.LTD operates an integrated industrial chain focused on animal health and nutrition. The company specializes in the research, development, and manufacturing of veterinary biological products, including a comprehensive range of vaccines and diagnostic reagents for livestock. Its operations encompass the production of high-quality animal feed and the management of large-scale breeding programs, with a primary focus on pig farming and meat processing. By leveraging advanced biotechnology and standardized production systems, the company provides comprehensive solutions for livestock management and food safety. Key activities include the formulation of specialized animal nutrition products and the implementation of rigorous biosecurity protocols across its facilities to ensure the quality and reliability of its agricultural outputs.

Recent filings

Filing Released Lang Actions
关于以债转股方式向全资子公司增资的进展公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Tian Kang Biological Co., Ltd. regarding the progress of capital increase to its wholly-owned subsidiaries through debt-to-equity conversion. It details the approval of the capital increase by the board and shareholders, the amount involved (21 billion yuan), and the completion of the registration changes with market regulatory authorities for the subsidiaries. The document is a formal public announcement about financing and capital structure changes, not a full financial report or audit. It does not contain financial statements or detailed financial analysis but focuses on the update of capital increase progress and related corporate actions. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is short (1826 characters), but it contains substantive information about financing activities rather than just announcing a report publication or regulatory filing. Hence, the classification is CAP with high confidence.
2024-10-30 Chinese
2024年三季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "天康生物股份有限公司2024 年第三季度报告" which translates to "Tiankang Biological Co., Ltd. 2024 Third Quarter Report." It contains detailed financial data including balance sheets, profit and loss statements, cash flow statements, and shareholder information for the third quarter of 2024. The document explicitly states it is a quarterly report and includes comprehensive financial statements and analysis for the period. It also mentions that the report is unaudited, which is typical for interim or quarterly reports. The length of the document (over 14,000 characters) and the presence of substantive financial data confirm it is a full interim/quarterly report rather than a brief announcement or certification. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). Q3 2024
2024-10-28 Chinese
关于天康生物股份有限公司2024年第五次临时股东大会之法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the convening, attendance, and voting procedures of the 2024 fifth extraordinary general meeting of shareholders of Tian Kang Bio. It details the legality of the meeting's call, the qualifications of attendees, and the voting results on specific proposals. The document is not a report of financial results, audit, or management discussion, but a legal opinion related to a shareholders meeting. It is not a simple announcement but a formal legal opinion letter. This type of document is best classified under Declaration of Voting Results & Voting Rights Announcements (DVA) because it includes detailed voting results and legal validation of the meeting and voting process.
2024-10-09 Chinese
关于2024年9月份生猪销售简报
Regulatory Filings Classification · 90% confidence The document is a sales brief for September 2024 from Tian Kang Biological Co., Ltd., detailing monthly and cumulative sales volumes and revenues of live pigs. It includes sales data, price trends, and risk warnings. The document is short (1702 characters), provides operational sales data for a specific month, and explicitly states that the data is unaudited and for investor reference only. It is not a full financial report, annual or interim, nor an earnings release summarizing quarterly results. It is a periodic sales update, which does not fit into categories like Annual Report, Interim Report, or Earnings Release. It is also not a regulatory filing, management change, or capital update. Given the nature and length, it best fits under Regulatory Filings (RNS) as a general regulatory announcement or operational update that does not fit other specific categories.
2024-10-09 Chinese
2024年第五次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled as a resolution announcement for the 2024 fifth extraordinary shareholders' meeting of Tiankang Biological Co., Ltd. It details the meeting date, attendance, voting results on specific proposals, and legal opinions on the meeting's validity. The content focuses on the official announcement of voting results from a shareholders' meeting, including percentages of votes for and against proposals. There is no detailed financial data, management discussion, or full report content. The document is relatively short (2085 characters) and serves as an official announcement of voting outcomes rather than the meeting materials or full report. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2024-10-09 Chinese
关于召开2024年第五次临时股东大会通知
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a detailed notice about the convening of the 2024 fifth extraordinary general meeting (临时股东大会) of Tian Kang Biological Co., Ltd. It includes information about the meeting date, voting procedures, agenda items, and proxy forms. It does not contain financial statements or results but is an announcement related to a shareholders' meeting. The document length is 4097 characters, which is relatively short and consistent with a meeting notice rather than a full report. The content matches the definition of a Proxy Solicitation & Information Statement (PSI), as it provides materials sent to shareholders to inform and request votes for the meeting. Therefore, the correct classification is PSI with high confidence.
2024-09-19 Chinese

Browse filings by year

21 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.